MCLE.OTC.PinkMedicale CORP

10-Q/A: Medicale Corp. Files Amended 10-Q/A for Q1 2025 to Correct Typographical Errors

Sentiment:

10-Q/A Amendment


Medicale Corp. files an amendment to its Q1 2025 10-Q report solely to correct typographical errors, with no material changes to the original filing.

Capital raiseManagement anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses.The Company intends to position itself so that it will be able to raise additional funds through the capital markets.
Worse than expectedThe company's working capital deficiency increased, indicating a worsening short-term financial position.The company has an accumulated deficit and has not yet commenced operations, indicating a lack of revenue generation.There is substantial doubt about the company's ability to continue as a going concern.

Summary

  • Medicale Corp. filed an amended quarterly report on Form 10-Q/A for the period ended December 31, 2024, to correct typographical errors.
  • The amendment does not reflect any subsequent events occurring after February 18, 2025, the date of the original filing.
  • The company's cash balance remained at $159 as of December 31, 2024.
  • The net loss for the three months ended December 31, 2024, was $16,680, compared to a net loss of $19,307 for the same period in 2023.
  • The company had a working capital deficiency of $22,028 as of December 31, 2024, compared to a deficiency of $15,348 as of September 30, 2024.
  • The company's accumulated deficit was $192,525 as of December 31, 2024.
  • The company has convertible notes payable totaling $93,585 as of December 31, 2024.
  • The company has not yet commenced any operations and is focused on preserving cash and raising capital.
  • There is substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's accumulated deficit, working capital deficiency, lack of operations, and going concern uncertainty. While the net loss decreased slightly, the overall financial position remains weak.

Positives

  • The net loss decreased by $2,627, from $19,307 in Q1 2023 to $16,680 in Q1 2024.
  • Cash flows used in operating activities decreased from $27,706 to $10,000.

Negatives

  • The company has a significant accumulated deficit of $192,525.
  • The company has a working capital deficiency of $22,028.
  • The company has not yet commenced operations.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • The company's disclosure controls and procedures were not effective as of December 31, 2024.

Risks

  • The company's ability to continue as a going concern is uncertain and dependent on raising additional capital.
  • The company has not yet commenced operations and may face challenges in establishing a successful business.
  • The company's disclosure controls and procedures were not effective as of December 31, 2024, which could lead to errors in financial reporting.
  • The company's sole officer and director reviews, evaluates, approves, and records transactions, which creates a lack of segregation of duties and increases the risk of errors or fraud.

Future Outlook

Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses and intends to position itself to raise additional funds through the capital markets.

Management Comments

  • Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses.
  • The Company intends to position itself so that it will be able to raise additional funds through the capital markets.

Industry Context

The company plans to offer consulting services and distribution of dietary supplements, which is a competitive market with established players. The company's success will depend on its ability to differentiate itself and gain market share.

Comparison to Industry Standards

  • It is difficult to compare Medicale Corp.'s results to industry standards due to its early stage and lack of operations.
  • Many companies in the dietary supplement industry, such as Herbalife Nutrition and Nature's Sunshine Products, have established distribution networks and significant revenue streams, which Medicale Corp. currently lacks.
  • The company's financial position is significantly weaker than established competitors, raising concerns about its ability to compete effectively.

Stakeholder Impact

  • Shareholders face significant risk due to the company's financial instability and uncertainty about its ability to continue as a going concern.
  • The company's employees (if any) may face job insecurity due to the company's financial challenges.
  • The company's creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

  • The company intends to position itself so that it will be able to raise additional funds through the capital markets.
  • The company needs to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time.

Key Dates

DateDescription
2020-08-17Medicale Corp. was incorporated in the State of Nevada.
2022-12-28Borisi Alborovi entered into a stock purchase agreement for the sale of 3,200,000 shares of Common Stock of the Company to Magenta Acres, Inc.
2022-12-28Borisi Alborovi, resigned his positions with the Company.
2023-01-01The Company ceased operations of its primary business of selling consumer products and accessories.
2023-01-09A change in control completed as the Company's former majority shareholder sold his 3,200,000 shares to an investor group.
2023-12-31The Company entered into a Convertible Note agreement with a third party at $48,186.
2024-03-31The Company entered into a Convertible Note agreement with a third party at $10,602.
2024-06-30The Company entered into a Convertible Note agreement with a third party at $9,288.
2024-08-19The Company filed its Annual Report on Form 10-K with the SEC.
2024-09-30The Company entered into a Convertible Note agreement with a third party at $15,509.
2024-12-31End of the quarterly period for which the amended report is filed.
2024-12-31The Company entered into a Convertible Note agreement with a third party at $10,000.
2025-01-14The Company's Form 10-K was filed with the Securities and Exchange Commission.
2025-02-18Original Form 10-Q was filed with the SEC.
2025-02-19Date of the amended filing (Form 10-Q/A).

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.